Jpmorgan Chase & CO Ascendis Pharma A/S Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Jpmorgan Chase & CO holds 185,122 shares of ASND stock, worth $38.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

185,122

Previous 77,427 139.09%

Holding current value

$38.6 Million

Previous $10.7 Million 170.69%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$119.49 - $168.84 $12.9 Million - $18.2 Million	107,695 Added 139.09%	185,122 $28.9 Million
Q4 2024 Feb 12, 2025	BUY	$122.0 - $146.6 $4.59 Million - $5.51 Million	37,593 Added 94.37%	77,427 $10.7 Million
Q3 2024 Dec 26, 2024	SELL	$113.0 - $153.43 $2.87 Million - $3.9 Million	-25,428 Reduced 38.96%	39,834 $5.95 Million
Q3 2024 Nov 08, 2024	SELL	$113.0 - $153.43 $2.87 Million - $3.9 Million	-25,428 Reduced 38.96%	39,834 $5.95 Million
Q2 2024 Dec 26, 2024	BUY	$121.07 - $153.67 $3.08 Million - $3.91 Million	25,428 Added 63.83%	65,262 $8.9 Million
Q2 2024 Aug 12, 2024	BUY	$121.07 - $153.67 $4.51 Million - $5.73 Million	37,256 Added 133.03%	65,262 $8.9 Million
Q1 2024 Dec 26, 2024	SELL	$123.45 - $159.4 $1.46 Million - $1.89 Million	-11,828 Reduced 29.69%	28,006 $4.23 Million
Q1 2024 May 10, 2024	SELL	$123.45 - $159.4 $4.18 Million - $5.4 Million	-33,858 Reduced 54.73%	28,006 $4.23 Million
Q4 2023 Dec 26, 2024	BUY	$86.1 - $127.36 $1.9 Million - $2.81 Million	22,030 Added 55.3%	61,864 $7.79 Million
Q4 2023 Feb 12, 2024	SELL	$86.1 - $127.36 $6.76 Million - $10 Million	-78,512 Reduced 55.93%	61,864 $7.79 Million
Q3 2023 Nov 14, 2023	BUY	$86.5 - $103.97 $279,481 - $335,927	3,231 Added 2.36%	140,376 $13.1 Million
Q2 2023 Aug 11, 2023	BUY	$69.96 - $97.84 $4.28 Million - $5.98 Million	61,148 Added 80.46%	137,145 $12.2 Million
Q1 2023 May 11, 2023	SELL	$104.9 - $126.78 $78,360 - $94,704	-747 Reduced 0.97%	75,997 $8.15 Million
Q4 2022 Feb 13, 2023	SELL	$99.42 - $131.97 $1.43 Million - $1.9 Million	-14,375 Reduced 15.78%	76,744 $9.37 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $2.78 Million - $3.65 Million	-33,092 Reduced 26.64%	91,119 $9.41 Million
Q2 2022 Aug 11, 2022	BUY	$78.08 - $117.61 $8.23 Million - $12.4 Million	105,402 Added 560.38%	124,211 $11.5 Million
Q1 2022 May 11, 2022	BUY	$102.18 - $135.75 $156,335 - $207,697	1,530 Added 8.85%	18,809 $2.21 Million
Q4 2021 Feb 10, 2022	BUY	$127.1 - $169.66 $1.31 Million - $1.75 Million	10,317 Added 148.19%	17,279 $2.32 Million
Q3 2021 Nov 12, 2021	BUY	$112.67 - $176.92 $784,408 - $1.23 Million	6,962 New	6,962 $1.11 Million

Others Institutions Holding ASND

# of Institutions

277

Shares Held

60M

Call Options Held

217K

Put Options Held

73.3K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $11.6B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Ascendis Pharma A/S Transaction History